In Vitro Activity of an Oral Streptogramin Antimicrobial, XRP2868, against Gram-Positive Bacteria
Open Access
- 1 July 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (7) , 3034-3039
- https://doi.org/10.1128/aac.49.7.3034-3039.2005
Abstract
The comparative in vitro potency of XRP2868, a new oral semisynthetic streptogramin antibiotic, was evaluated against gram-positive bacteria. XRP2868 inhibited all staphylococci at ≤1 μg/ml and all nonpneumococcal streptococci at ≤0.25 μg/ml and was fourfold more potent than quinupristin-dalfopristin against Staphylococcus aureus and Enterococcus faecium .Keywords
This publication has 6 references indexed in Scilit:
- Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and LactobacilliAntimicrobial Agents and Chemotherapy, 2005
- Activities of a New Oral Streptogramin, XRP 2868, Compared to Those of Other Agents against Streptococcus pneumoniae and Haemophilus SpeciesAntimicrobial Agents and Chemotherapy, 2003
- An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-DalfopristinAntimicrobial Agents and Chemotherapy, 2002
- A multicenter evaluation of linezolid antimicrobial activity in North AmericaDiagnostic Microbiology and Infectious Disease, 2002
- Safety and tolerability of quinupristin/dalfopristin: administration guidelinesJournal of Antimicrobial Chemotherapy, 1999
- Characterization of Vancomycin-Resistant Enterococcus faecium Isolates from the United States and Their Susceptibility In Vitro to Dalfopristin-QuinupristinAntimicrobial Agents and Chemotherapy, 1998